Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTC896 Gel in Acne Vulgaris
NCT02395549Phase 2Unknown
- Sponsor
- Mimetica
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MTC-896 in acne vulgaris (4 arms), sponsored by Mimetica. Primary endpoints: Absolute change from baseline in inflammatory lesion counts at 12 weeks, Absolute change from baseline in noninflammatory lesion counts at 12 weeks and 1 more. Status: unknown.
02
Drugs
MTC-896
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02395549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395549.